Top Markets
Coin of the day
Virpax Pharmaceuticals, Inc. Virpax Pharmaceuticals, Inc.

Virpax Pharmaceuticals, Inc.

VRPX
Kedudukan dalam Saham #42776
Virpax Pharmaceuticals, Inc. operates as a preclinical-stage pharmaceutical... Virpax Pharmaceuticals, Inc. operates as a preclinical-stage pharmaceutical enterprise, dedicated to pioneering diverse drug-delivery systems and novel drug-releasing technologies. Its core focus lies in developing advanced, non-opioid and non-addictive solutions for pain management, alongside therapies targeting central nervous system disorders. The company's current investigational pipeline features several preclinical product candidates. These include Epoladerm, a topical nonsteroidal anti-inflammatory drug (NSAID) designed to address chronic osteoarthritis of the knee, and Probudur, an injectable liposomal gel formulated as a local anesthetic for managing post-operative pain. Also in development are Envelta and PES200, both nanotechnology-based intranasal spray drug candidates engineered to deliver metabolically labile peptide drugs directly to the brain. Further candidates comprise AnQlar, an antiviral barrier solution intended to prevent or lessen the severity of human viral infections such as influenza and SARS-CoV-2, and VRP324, an experimental nasal formulation aimed at enhancing the transport of cannabidiol into the brain. Virpax Pharmaceuticals, Inc. was established in 2016 and is based in Berwyn, Pennsylvania.
Harga Saham
$0.0001
Disegerakkan terakhir: 2026-08-11
Modal Pasaran
$124.00
Perubahan (1 hari)
0.00%
Perubahan (1 tahun)
-99.09%
Negara
US
Perdagangan Virpax Pharmaceuticals, Inc. (VRPX)

Kategori

Pendapatan untuk Virpax Pharmaceuticals, Inc. (VRPX)
Pendapatan pada 2026 TTM: 0
Menurut laporan kewangan terkini Virpax Pharmaceuticals, Inc., pendapatan semasa syarikat ialah 0. Pada tahun 2026, syarikat memperoleh pendapatan sebanyak 0, sama dengan pendapatan pada tahun 2026 yang berjumlah 0. Pendapatan yang dipaparkan di halaman ini adalah pendapatan sebelum faedah dan cukai atau dikenali sebagai EBIT.
Sejarah pendapatan bagi Virpax Pharmaceuticals, Inc. dari 2026 hingga 2026
Pendapatan pada akhir setiap tahun
Tahun Pendapatan Ubah
Tidak cukup data untuk tarikh yang disediakan.
Pendapatan untuk syarikat atau pesaing serupa
Syarikat Pendapatan Perbezaan Pendapatan Negara
$5.27B -
US
$1.95B -
NL
- -
CH
$3.01B -
BE
- -
KR